Intuitive Surgical, Inc. $ISRG Stock Position Trimmed by Curated Wealth Partners LLC

Curated Wealth Partners LLC lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 98.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,234 shares of the medical equipment provider’s stock after selling 156,197 shares during the period. Curated Wealth Partners LLC’s holdings in Intuitive Surgical were worth $908,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ISRG. Main Street Group LTD bought a new position in Intuitive Surgical in the 1st quarter valued at $30,000. North Point Portfolio Managers Corp OH acquired a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $27,000. Vermillion Wealth Management Inc. increased its stake in shares of Intuitive Surgical by 58.1% in the 1st quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 25 shares during the period. Evergreen Advisors LLC bought a new stake in shares of Intuitive Surgical during the first quarter worth $35,000. Finally, Compass Financial Management LLC bought a new stake in shares of Intuitive Surgical during the second quarter worth $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $427.86 on Friday. The firm’s 50 day moving average price is $390.47 and its two-hundred day moving average price is $409.62. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88. The stock has a market cap of $151.15 billion, a PE ratio of 49.01, a PEG ratio of 3.17 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. The company had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.81 EPS. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the transaction, the executive vice president directly owned 5,320 shares in the company, valued at $2,016,280. This trade represents a 6.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 400 shares of Intuitive Surgical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the sale, the director directly owned 251 shares of the company’s stock, valued at approximately $95,129. This trade represents a 61.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,370 shares of company stock worth $4,891,989 over the last 90 days. 0.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ISRG. Oppenheimer raised Intuitive Surgical from a “market perform” rating to an “outperform” rating and set a $500.00 price target on the stock in a research note on Wednesday, August 12th. JPMorgan Chase & Co. decreased their price target on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating on the stock in a report on Friday, July 17th. Evercore set a $430.00 price objective on Intuitive Surgical in a research report on Monday, July 6th. UBS Group reiterated a “buy” rating on shares of Intuitive Surgical in a research report on Tuesday. Finally, Barclays raised Intuitive Surgical to a “strong-buy” rating in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $498.83.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical outperformed the broader market in the latest session, supported by its long-term growth profile and investor interest ahead of earnings. The company’s most recent quarterly results also showed strong momentum, with earnings and revenue exceeding analyst expectations and revenue rising 18.4% year over year. Intuitive Surgical Beats Stock Market Upswing
• Positive Sentiment: Analysts are watching da Vinci 5 adoption, Ion procedures, surgical-system placements and recurring instrument and accessory revenue as potential indicators of another strong quarter. These operating metrics could provide more insight than revenue and earnings per share alone. Countdown to Intuitive Surgical Q3 Earnings
• Positive Sentiment: Erste Group Bank marginally raised its fiscal 2026 earnings forecast to $8.94 per share, above the approximately $8.87 consensus estimate, signaling modestly improved expectations for profitability.
• Neutral Sentiment: Intuitive Surgical has gained nearly 12% over the past month, making the upcoming earnings release an important catalyst for whether the recent rally can continue. Analysts also highlight the company as a sales-growth stock, with strong projected revenue expansion for 2026. ISRG Gains Nearly 12% in a Month
• Negative Sentiment: Valuation remains a concern: ISRG trades at roughly 49 times earnings, and one analysis estimates the shares could be about 31% overvalued even after an improved earnings outlook. Any weaker-than-expected Q3 metrics or cautious guidance could pressure the stock. Intuitive Surgical Could Be 31% Overvalued

About Intuitive Surgical

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.